|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrations within the phosphoinositide-3-kinase (PI3K) pathway occur in greater than 45% of ovarian carcinomas.
|
21970855 |
2011 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer.
|
29371953 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer.
|
30129654 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the phosphatidylinositol 3' kinase (PI3K) pathway occurs in a significant fraction of both types of ovarian cancer, driven predominantly by mutations in type I and amplification in type II.
|
22585163 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway.
|
23408974 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
|
24036443 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAF: cancer-associated fibroblasts; COG: Cluster of Orthologous Groups; DEA: disease enrichment analysis; EOC: epithelial ovarian carcinoma; ESCC: oesophageal squamous cell carcinoma; GSI: gamma secretase inhibitor; GO: Gene Ontology; GSEA: gene set enrichment analyzes; HAS: Hungarian Academy of Sciences; lncRNAs: long non-coding RNAs; MAPK/ERK: mitogen-activated protein kinase/extracellular signal-regulated kinases; NGS: next-generation sequencing; ncRNAs: non-coding RNAs; OvC: ovarian cancer; PI3K/Akt/mTOR: phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin; RT-PCR: real-time polymerase chain reaction; SNP: single nucleotide polymorphism; TF: transcription factor; TGF-β: transforming growth factor-β.
|
28574782 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.
|
30925458 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
|
26983899 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-targeting IKKβ and PI3K pathways downstream of GAB2 might be a promising therapeutic strategy for ovarian cancer that overexpresses GAB2.
|
26657155 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggested that combined inhibition of PI3K and PARP may be an effective therapeutic strategy for ovarian cancers with PIK3CA mutations and that the accompanied BRCA downregulation following PI3K inhibition could serve as a biomarker for the effective response to PARP inhibition.
|
26909613 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conditional suppression of functional p53 increased p110alpha transcripts, protein levels and PI3K activity in immortalized, non-tumorigenic ovarian surface epithelial (OSE) cells, the precursors of ovarian carcinoma.
|
18270270 |
2008 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, the addition of a PI3K inhibitor to CDDP-based chemotherapy may have a more beneficial application for ovarian cancer therapy.
|
23970345 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and RAS/extracellular signal-regulated kinase (ERK) pathways is common in ovarian cancer, providing potential new targets for 2nd line therapy.
|
24011934 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
|
29930760 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
|
27082164 |
2016 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
|
25852062 |
2015 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.
|
29743815 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we identified the molecular mechanism that limits the efficacy of the beta-sparing PI3Ki, Taselisib (GDC0032), in PIK3CA-mutated OC cell lines (IGROV1 and OAW42) that acquired resistance to GDC0032.
|
30237504 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant.
|
22340595 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
High prevalence of genetic alterations in PI3K/AKT pathway in a Middle Eastern ovarian carcinoma provides genetic evidence supporting the notion that dysregulated PI3K/AKT pathways play an important role in the pathogenesis of ovarian cancers.
|
19638206 |
2009 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF/PI3K/AKT signaling pathway also plays certain roles in the program and regulation of human breast cancer and ovary cancer.
|
22094188 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have investigated the expression profile of 22 genes involved in the PI3K-AKT pathway in 26 high-grade ovarian carcinomas (19 serous and 7 clear cell carcinomas).
|
21317880 |
2011 |